CDSCO Registration & Approval in India 2026: Process, Documents, Fees & Requirements
CDSCO registration or approval is the mandatory regulatory process through which applicable drugs, new chemical entities, medical devices, diagnostics, and clinical trials are evaluated, licensed, and monitored in India. Supervised by the Central Drugs Standard Control Organization (CDSCO) under the Ministry of Health and Family Welfare, the exact approval pathway—including required forms, dossier requirements, testing protocols, fees, and processing times—depends entirely on the regulatory classification, risk level, and origin of your product.
Whether you are an Indian drug manufacturer, a global pharmaceutical enterprise seeking a marketing authorization route, a medical device developer, or a clinical research sponsor, navigating the Indian healthcare regulatory framework requires selecting the exact statutory pathway before filing a submission.
One of the most common causes of regulatory delay is attempting to apply a single, generalized "CDSCO license" concept across all product lines. India enforces strictly segregated regulatory tracks: the Drugs and Cosmetics Rules, 1945, the Medical Devices Rules, 2017 (MDR 2017), and the New Drugs and Clinical Trials Rules, 2019 (NDCT Rules 2019). Identifying your product’s precise governing framework is the critical first step before assembling technical dossiers or executing clinical trials.
Which CDSCO Approval Do You Need? (Pathway Decision Guide)
To determine your exact submission track, identify your product type and core activity in the decision table below:
CDSCO Registration at a Glance
What Is CDSCO?
The Central Drugs Standard Control Organization (CDSCO) is the national regulatory body for Indian pharmaceuticals and medical devices. Functioning under the Directorate General of Health Services (DGHS) within the Ministry of Health and Family Welfare, CDSCO derives its statutory authority from the Drugs and Cosmetics Act, 1940 and its associated rules.
Headheaded by the Drugs Controller General of India (DCGI), CDSCO acts as the Central Licensing Authority (CLA). It works in conjunction with various State Licensing Authorities (SLAs) across India:
Central Licensing Authority (CLA / CDSCO HQ): Controls the approval of new drugs, investigational new drugs (INDs), clinical trial permissions, registration of foreign manufacturing sites, import licenses for drugs and devices, and manufacturing permissions for high-risk (Class C and D) medical devices.
State Licensing Authorities (SLAs): Grant licenses for domestic drug manufacturing facilities, sale and distribution licenses, and manufacturing licenses for low-to-moderate-risk (Class A and B) medical devices.
What Does CDSCO Regulate?
CDSCO’s mandate is divided into four major regulatory sectors:
Pharmaceuticals & APIs: Standard drugs, bulk drug substances (APIs), fixed-dose combinations (FDCs), blood products, vaccines, biosimilars, and imported drug formulations.
New Drugs & Investigational New Drugs (INDs): Substances not previously authorized in India, including new chemical entities (NCEs), biological products, novel drug delivery systems (NDDS), and new therapeutic indications.
Clinical Trials: Ethics committee oversight, permissions for human clinical trials (Phases I–IV), bioequivalence studies, and Global Clinical Trials (GCTs) conducted within India.
Medical Devices & In-Vitro Diagnostics (IVDs): Risk-classified medical hardware, software, implants, and diagnostic kits governed by dedicated statutory risk thresholds.
CDSCO Regulatory Framework in India
All CDSCO activities follow a defined legal hierarchy:
Drugs & Cosmetics Act, 1940
Drugs & Cosmetics Rules, 1945
Medical Devices Rules, 2017 New Drugs & Clinical Trials Rules, 2019
(MDR 2017 - Devices & IVDs) (NDCT Rules 2019 - NCEs & CTs)
CDSCO Notifications / Circulars / Guidelines
Product-Specific Technical Guidelines
Under this structure, MDR 2017 governs medical devices and IVDs separately from standard drug formulations, while NDCT Rules 2019 regulates new drug approvals, clinical trial applications, investigational products, and ethics committees.
Distinguishing CDSCO Terminology: Registration vs. Approval vs. License
Using precise terminology prevents administrative confusion during official filings:
CDSCO Approval / Permission: The statutory evaluation and marketing authorization granted for a New Drug, IND, or Clinical Trial Protocol.
CDSCO Import Registration Certificate: The official document confirming that an overseas drug or API manufacturing facility complies with Indian standards (e.g., Form 41).
CDSCO License: The operational authority granted to import, manufacture, or sell drugs or medical devices (e.g., Form 10 Drug Import License, Form MD-15 Device Import License, Form MD-9 Class C/D Manufacturing License).
Marketing Authorization: Formal permission allowing an entity to distribute and commercialize an approved therapeutic product within the Indian territory.
The CDSCO SUGAM Digital Portal
The SUGAM Portal (cdscosugam.gov.in) is CDSCO’s unified e-governance platform. It handles submissions, technical document uploads, tracking, query responses, and approval downloads.
Core SUGAM Functionalities
Organization & User Registration: Setup of corporate profile and verification of statutory documents (PAN, IEC, Wholesale License/Manufacturing License).
Application Submission: Uploading common technical dossiers (CTD), device master files (DMF), and clinical trial protocols.
Fee Integration: Direct payment linking to the Government of India’s Bharatkosh payment portal.
Real-time Query Management: Automated notifications for regulatory queries raised during technical evaluations.
Major Regulatory Update: IND Division Clarification
Key Regulatory Update: August 10 Circular
Subject: Processing Route for Unapproved New Drugs with Indian Phase III GCT Data
Authority: Central Drugs Standard Control Organization (HQ), New Delhi
CDSCO issued a critical procedural clarification regarding applications seeking permission to import and market new drugs that are not approved anywhere in the world, but where Phase III Global Clinical Trials (GCTs) have been completed or are ongoing with the participation of Indian subjects.
Designated Division: Such applications are examined and processed directly by the Investigational New Drug (IND) Division, CDSCO Headquarters, New Delhi.
Applicable Framework: Processed under the statutory provisions of the New Drugs and Clinical Trials Rules, 2019.
Scope & Exclusion: This clarification applies specifically to the described class of globally unapproved new drugs with Indian trial participation. It does not alter the standard pathway for drugs already approved in foreign jurisdictions or standard generic import routes.
What Is the Role of the IND Division?
The Investigational New Drug (IND) Division handles investigational chemical and biological entities. It reviews early-stage clinical trial approvals, evaluates non-clinical safety/pharmacology datasets, monitors global clinical trial entries into India, and coordinates pre- and post-submission meetings through Subject Expert Committees (SECs).
Does Completing Phase III Clinical Trials Mean Automatic CDSCO Approval?
No. Completing Phase III Global Clinical Trials—even with Indian patient enrollment—does not grant automatic marketing authorization or an import license in India.
Phase III trials generate clinical data to evaluate safety and efficacy, but CDSCO’s evaluation considers additional criteria:
Risk-Benefit Balance for the Indian Population: Evaluating efficacy data against standard care practices in India.
Quality Control & CMC Documentation: Assessment of Chemistry, Manufacturing, and Controls, stability data under Zone IVb climate conditions (30°C / 75% RH), and process validation.
Local Post-Marketing Commitments: Requirement for Phase IV (post-marketing) clinical studies or active pharmacovigilance commitments within India.
CDSCO Pharmaceutical Registration Pathways
Pharmaceutical product approvals follow three distinct tracks depending on the product's regulatory history in India.
1. Existing Drugs (Approved in India for > 4 Years)
Route: Standard Registration and Import Licensing under the Drugs & Cosmetics Rules, 1945.
Forms: Form 40 (Registration Certificate for foreign site) and Form 10 (Import License for local importer).
Key Requirements: Proof of existing approval in India, Good Manufacturing Practice (GMP) certificates, process validation, and stability testing reports.
2. New Drugs (Unapproved or Approved < 4 Years)
Route: New Drug Application (NDA) under NDCT Rules, 2019.
Key Requirements: SEC technical review, comprehensive non-clinical toxicology reports, Phase I–III clinical data, CMC technical dossiers, and proposed package inserts.
3. Active Pharmaceutical Ingredients (APIs / Bulk Drugs)
Route: Bulk Drug Registration Certificate (Form 41) or inclusion in the Finished Dosage Form dossier via a Drug Master File (DMF).
Key Requirements: Complete DMF (Open and Closed parts), characterization of impurities, stability profile, and site inspectability.
CDSCO New Drug Approval Process
The lifecycle of a New Drug Application (NDA) or Investigational New Drug (IND) follows a multi-stage review process:
Classification: Verify whether the substance qualifies as an NCE, Biological, Biosimilar, or Fixed-Dose Combination (FDC).
Dossier Assembly: Prepare Module 1 (Administrative Information), Module 2 (CTD Summaries), Module 3 (CMC/Quality Data), Module 4 (Non-clinical Study Reports), and Module 5 (Clinical Study Reports).
Submission: File via SUGAM under the relevant NDCT Form track.
Preliminary Scrutiny: CDSCO checks for completeness of administrative documents and regulatory fees.
SEC Review: Presentation of clinical safety, efficacy, and therapeutic rationale before the relevant Subject Expert Committee (SEC).
Query Resolution: Submission of additional data or protocol amendments requested by the committee.
Approval Issue: Grant of formal marketing authorization or trial permission (e.g., Form CT-20 for import/market or Form CT-23 for domestic manufacture).
Post-Approval Compliance: Mandatory execution of Phase IV studies (if mandated) and submission of Periodic Safety Update Reports (PSURs).
CDSCO Clinical Trial Approval Framework
Clinical research conducted in India must comply with the New Drugs and Clinical Trials Rules, 2019 and the Good Clinical Practice (GCP) guidelines of India.
Core Elements of Clinical Trial Approvals
Ethics Committee (EC) Registration: All trials must be approved by an Ethics Committee registered with CDSCO under the NDCT Rules.
CTRI Registration: Clinical trials must be registered in the Clinical Trials Registry - India (CTRI) before enrolling the first subject.
Subject Compensation & Insurance: Strict compliance with statutory requirements for medical management and financial compensation in cases of trial-related injury or death.
CDSCO Medical Device Registration & Classification
Medical devices and In-Vitro Diagnostics (IVDs) in India are regulated based on a four-tier, risk-adjusted scale under the Medical Devices Rules, 2017 (MDR 2017).
Device Classification & Approval Architecture
Medical Device Licensing Steps (Import vs. Manufacture)
Route 1: Imported Medical Devices (Foreign Manufacturers)
Overseas Manufacturer - Appoint Indian Authorized Agent (IAA)
Compile Technical Dossier & Device Master File
Submit Form MD-14 via Online Device Portal
CDSCO Scrutiny & Document Verification
Issue of Import License (Form MD-15)
Route 2: Indian Manufactured Devices
Domestic Manufacturer - Implement ISO 13485 QMS
Submit Application: MD-3 (Class A/B) or MD-7 (Class C/D)
Audit by Notified Body (Class B) / CDSCO Team (Class C/D)
Issue of Manufacturing License: MD-5 (SLA) or MD-9 (CLA)
Key Statutory Medical Device Forms
Documents Required for CDSCO Applications
Documents must be structured according to the relevant product track:
Documentation Architecture
Pharmaceuticals & APIs New Drugs & INDs Medical Devices & IVDs
• Form 40/10 Application • CTD Modules 1 to 5 • Device Master File (DMF)
• ISO/GMP Certificates • Pre-clinical Study Data • Plant Master File (PMF)
• Certificate of Analysis • Human Clinical Reports • ISO 13485 Certificate
• Stability Data (Zone IVb) • Complete CMC Data • Essential Principles Check
• Package Inserts/Labels • Investigator Brochure • Clinical Performance Evidence
CDSCO Fees Structure (Overview)
CDSCO fees are statutory and payable in USD for overseas sites/imports or INR for domestic applications via the government portal Bharatkosh.
CDSCO Fee Determination Factors
Product Type Site & Scale Process Track
(Drug, Device, NCE) (Single/Multiple Sites) (Import vs Domestic)
Fee Variables
Manufacturing Site Inspection Fee: Applied per overseas manufacturing facility for drug or device imports.
Per-Product / Per-Distinct Model Fee: Applied individually to each drug formulation, API, or distinct medical device family model.
Clinical Trial Review Fee: Varies based on Phase (Phase I vs Phase II–IV) and whether the protocol is part of an IND track.
(Note: Applicants must verify exact statutory fee schedules on the official SUGAM/Bharatkosh payment portals prior to transaction submission.)
Approval Timelines
CDSCO processing times vary based on technical complexity and committee reviews:
Typical Approval Horizons (Indicative Timeline Windows)
Existing Drug Import (Form 10) │ 3 to 6 Months
Class A/B Device License │ 2 to 4 Months
Class C/D Device License │ 4 to 9 Months
New Drug / NDA Approval │ 6 to 12+ Months
IND / Clinical Trial Approval │ 3 to 6 Months
Common Timeline Variables:
Speed and clarity of applicant responses to regulatory queries raised during technical reviews.
Scheduling dates for Subject Expert Committee (SEC) meetings.
Physical audit timing for manufacturing facilities (domestic or international).
CDSCO Approval Requirements for Foreign Manufacturers
Foreign manufacturers without a registered office in India cannot submit applications directly to CDSCO.
Foreign Manufacturer (Overseas Legal Entity)
│
Execution of Power of Attorney (PoA)
│
Indian Authorized Agent (IAA - Resident Entity)
│ (Wholesale License / ISO)
SUGAM Portal Submission & Legal Liability
Role of the Indian Authorized Agent (IAA)
Must hold a valid wholesale drug license or medical device registration in India.
Acts as the statutory representative responsible for regulatory correspondence, query responses, and post-market safety reporting.
Remains joint-severally liable for quality, safety, and pharmacovigilance compliance for products sold in India.
Post-Approval Compliance & Lifecycle Management
Compliance continues after an import or manufacturing license is issued.
Post-Approval Lifecycle
Pharmacovigilance Quality Changes License Maintenance
• Adverse Event Tracking • Minor Variations • Perpetual Validity Compliance
• Mandatory PSUR Filings • Major Variations • Retention Fee Payments
• Materiovigilance (Devices) • Site/Process Updates • Inspection Readiness
Pharmacovigilance Program of India (PvPI): License holders must track adverse drug reactions (ADRs) and submit Periodic Safety Update Reports (PSURs).
Materiovigilance Program of India (MvPI): Medical device importers and manufacturers must report Adverse Events (AEs) related to device usage.
Post-Approval Changes (Variations): Any changes to manufacturing sites, composition, shelf-life, or packaging require filing prior notifications or formal variation applications with CDSCO.
Institutional Regulatory Entities: Reference Matrix
Common CDSCO Application Mistakes
Avoiding these common filing mistakes helps prevent delays or application rejections:
Pathway Misalignment: Applying under generic Drug rules for products classified as Medical Devices or Novel Delivery Systems.
Incorrect Device Classification: Self-assessing a device as Class A or B without reviewing formal CDSCO dynamic classification lists.
Inadequate Stability Testing: Submitting stability data conducted under climate conditions other than Zone IVb (30°C / 75% RH).
Inconsistent Master Files: Mismatches between the Plant Master File, Device Master File, and submitted product labels.
Unclear Power of Attorney (PoA): Submitting overseas agent authorization documents that lack legal notarization or apostille authentication.
Slow Query Responses: Failing to respond to official CDSCO portal queries within stipulated timelines.
CDSCO Application Readiness Checklist
Before filing an application via SUGAM or the Medical Device portal, verify the following items:
Product classification confirmed via CDSCO guidance documents.
Governing statutory pathway identified (Drugs & Cosmetics Rules / MDR 2017 / NDCT Rules 2019).
Indian Authorized Agent (IAA) formally appointed with notarized/apostilled PoA (for foreign manufacturers).
Active SUGAM / Device Portal corporate user accounts set up.
Common Technical Document (CTD) or Device Master File (DMF) assembled.
Climate Zone IVb stability testing reports prepared.
Good Manufacturing Practice (GMP) or ISO 13485 certificates validated.
Draft artwork, outer box labels, and package inserts updated for Indian regulatory requirements.
Bharatkosh fee payment routing verified.
Post-market surveillance/pharmacovigilance workflow established.
2026 Regulatory Changes Log
To remain accurate over time, this guide maintains a change log tracking updates to Indian healthcare regulations:
August 2026 (IND Division Guidance): CDSCO issued a circular clarifying that applications for unapproved global new drugs backed by Phase III Global Clinical Trials with Indian subject participation are processed directly by the IND Division (HQ) under the NDCT Rules 2019.
January 2026 (NDCT Amendment Rules): Updates regarding test-license exemptions and streamlined bioequivalence study rules under Rule 52 of the NDCT framework.
Frequently Asked Questions
1. What is CDSCO registration?
CDSCO registration is the official statutory process by which drugs, new chemical entities, medical devices, diagnostics, and clinical trial protocols are evaluated and granted marketing, import, or manufacturing authorization in India.
2. Is CDSCO registration the same as a CDSCO license?
No. An approval or registration validates that a product's technical, safety, and clinical data complies with Indian standards. A license (e.g., Form 10, Form MD-15, Form MD-9) provides statutory operational permission to import or manufacture that approved product.
3. Can a foreign company apply directly to CDSCO?
No. Overseas entities must appoint an Indian Authorized Agent (IAA)—a legally registered Indian company holding valid distribution or manufacturing licenses—to submit applications and hold regulatory responsibility.
4. What is the SUGAM Portal?
SUGAM is CDSCO’s central online portal. It is used to submit, process, track, and issue regulatory approvals for pharmaceuticals, bulk drugs, clinical trials, and regulatory variations.
5. How are medical devices classified under CDSCO?
Medical devices are categorized into four risk-based tiers under the Medical Devices Rules, 2017: Class A (Low risk), Class B (Low-moderate risk), Class C (Moderate-high risk), and Class D (High risk).
6. What did the CDSCO Circular of 10 August 2026 clarify?
The circular clarified that applications for globally unapproved new drugs supported by ongoing or completed Phase III Global Clinical Trials with Indian patient participation must be submitted directly to and evaluated by the IND Division at CDSCO Headquarters, New Delhi.
7. Does Phase III completion automatically yield marketing approval in India?
No. Phase III clinical trial completion generates safety and efficacy datasets, but CDSCO independently reviews CMC documentation, local risk-benefit factors, stability, and label compliance before issuing marketing authorization.
Conclusion
Navigating CDSCO approval requires aligning your product with its correct statutory framework—whether under the Drugs and Cosmetics Rules, MDR 2017, or NDCT Rules 2019. Success depends on accurate risk classification, complete technical dossiers, and diligent post-approval compliance. Applicants should verify all technical parameters before filing through the official SUGAM or Medical Device portals.
Source: https://www.tumblr.com/crscertificate/825536650096574464/cdsco-registration-approval-in-india-2026
Comments
Post a Comment